The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study
Abstract
:1. Introduction
2. Results
2.1. Tumor Characteristics
2.2. 18F-FDG PET/CT Evaluation for Initial Staging
2.3. Role of 18F-FDG PET/CT in Predicting Survival
Application of Deauville Criteria
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. 18F-FDG PET/CT Imaging and Interpretation
4.3. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Vose, J.M. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am. J. Hematol. 2017, 92, 806–813. [Google Scholar] [CrossRef] [PubMed]
- Hoster, E.; Dreyling, M.; Klapper, W.; Gisselbrecht, C.; van Hoof, A.; Kluin-Nelemans, H.C.; Pfreundschuh, M.; Reiser, M.; Metzner, B.; Einsele, H.; et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111, 558–565. [Google Scholar] [CrossRef] [PubMed]
- Barrington, S.F.; Mikhaeel, N.G.; Kostakoglu, L.; Meignan, M.; Hutchings, M.; Müeller, S.P.; Schwartz, L.H.; Zucca, E.; Fisher, R.I.; Trotman, J.; et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J. Clin. Oncol. 2014, 32, 3048–3058. [Google Scholar] [CrossRef] [PubMed]
- Cheson, B.D.; Fisher, R.I.; Barrington, S.F.; Cavalli, F.; Schwartz, L.H.; Zucca, E.; Lister, T.A. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. 2014, 32, 3059–3068. [Google Scholar] [CrossRef] [PubMed]
- Bailly, C.; Carlier, T.; Touzeau, C.; Arlicot, N.; Kraeber-Bodéré, F.; Le Gouill, S.; Bodet-Milin, C. Interest of FDG-PET in the Management of Mantle Cell Lymphoma. Front Med (Lausanne) 2019, 6, 70. [Google Scholar] [CrossRef]
- Maddocks, K. Update on Mantle cell lymphoma. Blood 2018, 132, 1647–1656. [Google Scholar] [CrossRef]
- Gill, S.; Wolf, M.; Prince, H.M.; Januszewicz, H.; Ritchie, D.; Hicks, R.J.; Seymour, J.F. 18F Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with Mantle cell lymphoma. Clin. Lymphoma Myeloma 2008, 8, 158–165. [Google Scholar] [CrossRef]
- Alavi, A.; Shrikanthan, S.; Aydin, A.; Talanow, R.; Schuster, S. Fluorodeoxyglucose-positron-emission tomography findings in Mantle cell lymphoma. Clin. Lymphoma Myeloma Leuk. 2011, 11, 261–266. [Google Scholar] [CrossRef]
- Albano, D.; Ferro, P.; Bosio, G.; Fallanca, F.; Re, A.; Tucci, A.; Ferreri, A.J.M.; Angelillo, P.; Gianolli, L.; Giubbini, R.; et al. Diagnostic and Clinical Impact of Staging 18F-FDG PET/CT in Mantle-Cell Lymphoma: A Two-Center Experience. Clin. Lymphoma Myeloma Leuk. 2019, 19, e457–e464. [Google Scholar] [CrossRef]
- Brepoels, L.; Stroobants, S.; De Wever, W.; Dierickx, D.; Vandenberghe, P.; Thomas, J.; Mortelmans, L.; Verhoef, G.; De Wolf-Peeters, C. Positron emission tomography in mantle cell lymphoma. Leuk. Lymphoma 2008, 49, 1693–1701. [Google Scholar] [CrossRef]
- Cohen, J.B.; Hall, N.C.; Ruppert, A.S.; Jones, J.A.; Porcu, P.; Baiocchi, R.; Christian, B.A.; Penza, S.; Benson, D.M.; Flynn, J.; et al. Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma. Bone Marrow Transplant. 2013, 48, 1212–1217. [Google Scholar] [CrossRef] [PubMed]
- Hosein, P.J.; Pastorini, V.H.; Paes, F.M.; Eber, D.; Chapman, J.R.; Serafini, A.N.; Alizadeh, A.A.; Lossos, I.S. Utility of positron emission tomography scans in mantle cell lymphoma. Am. J. Hematol. 2011, 86, 841–845. [Google Scholar] [CrossRef] [PubMed]
- Morgan, R.; Perry, M.; Kwak, J.; Jensen, A.; Kamdar, M. Positron emission tomography-based analysis can accurately predict bone marrow involvement with Mantle Cell Lymphoma. Clin. Lymphoma Myeloma Leuk. 2018, 18, 731–736. [Google Scholar] [CrossRef] [PubMed]
- Adams, H.J.A.; Kwee, T.C.; de Keizer, B.; Fijnheer, R.; de Klerk, J.M.; Littooij, A.S.; Nievelstein, R.A. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: Is bone marrow biopsy still necessary? Ann. Oncol. 2014, 25, 921–927. [Google Scholar] [CrossRef]
- Adams, H.J.A.; Kwee, T.C.; de Keizer, B.; Fijnheer, R.; de Klerk, J.M.; Nievelstein, R.A. FDG PET/CT for the detection of bone marrow involvement in diffuse large B cell lymphoma: Systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 565–574. [Google Scholar] [CrossRef]
- Bodet-Milin, C.; Touzeau, C.; Leux, C.; Sahin, M.; Moreau, A.; Maisonneuve, H.; Morineau, N.; Jardel, H.; Moreau, P.; Gallazini-Crépin, C.; et al. Prognostic impact of 18F-fluorodeoxyglucose positron emission tomography in untreated mantle cell lymphoma: A retrospective study from GOELAMS group. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 1633–1642. [Google Scholar] [CrossRef]
- Gontier, E.; Fourme, E.; Wartski, M.; Blondet, C.; Bonardel, G.; Le Stanc, E.; Mantzarides, M.; Foehrenbach, H.; Pecking, A.P.; Alberini, J.L. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 95–99. [Google Scholar] [CrossRef]
- Bybel, B.; Greenberg, I.D.; Paterson, J.; Ducharme, J.; Leslie, W.D. Increased F-18 FDG intestinal uptake in diabetic patients on metformin: A matched case-control analysis. Clin. Nucl. Med. 2011, 36, 452–456. [Google Scholar] [CrossRef]
- Shah, J.J.; Fayad, L.; Romaguera, J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 2008, 112, 2583. [Google Scholar] [CrossRef]
- Mato, A.R.; Svodoba, J.; Feldman, T.; Zielonka, T.; Agress, H.; Panush, D.; Miller, M.; Toth, P.; Lizotte, P.M.; Nasta, S.; et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer 2012, 118, 3565–3570. [Google Scholar] [CrossRef]
- Tiemann, M.; Schrader, C.; Klapper, W.; Dreyling, M.H.; Campo, E.; Norton, A.; Berger, F.; Kluin, P.; Ott, G.; Pileri, S.; et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br. J. Haematol. 2005, 131, 29–38. [Google Scholar] [CrossRef] [PubMed]
- Lamonica, D.; Graf, D.A.; Munteanu, M.C.; Czuczman, M.S. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab. J. Nucl. Med. 2017, 58, 62–68. [Google Scholar] [CrossRef] [PubMed]
- Bailly, C.; Carlier, T.; Barriolo-Rieding, A.; Casasnovas, O.; Gyan, E.; Meignan, M.; Moreau, A.; Burroni, B.; Djaileb, L.; Gressin, R.; et al. Prognostic value of FDG-PET in patients with mantle cell lymphoma: Results from the LyMa-PET Project. Haematologica 2019. [Google Scholar] [CrossRef] [PubMed]
- Albano, D.; Bosio, G.; Bianchetti, N.; Pagani, C.; Re, A.; Tucci, A.; Giubbini, R.; Bertagna, F. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. Ann. Nucl. Med. 2019, 33, 449–458. [Google Scholar] [CrossRef]
- Kedmi, M.; Avivi, I.; Ribakovsky, E.; Benyamini, N.; Davidson, T.; Goshen, E.; Tadmor, T.; Nagler, A.; Avigdor, A. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma? Leuk. Lymphoma 2014, 55, 2484–2489. [Google Scholar] [CrossRef]
- Meignan, M.; Gallamini, A.; Haioun, C.; Polliack, A. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010. Leuk Lymphoma. 2010, 51, 2171–2180. [Google Scholar] [CrossRef]
- Fallanca, F.; Alongi, P.; Incerti, E.; Ginaolli, L.; Picchio, M.; Kayani, I.; Bomanji, J. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: A comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 1837–1840. [Google Scholar] [CrossRef]
- Klener, P.; Fronkova, E.; Belada, D.; Forsterova, K.; Pytlik, R.; Kalinova, M.; Simkovic, M.; Salek, D.; Mocikova, H.; Prochazka, V.; et al. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematol. Oncol. 2018, 36, 110–115. [Google Scholar] [CrossRef]
- Czuczman, M.S.; Goy, A.; Lamonica, D.; Graf, D.A.; Munteanu, M.C.; van der Jagt, R.H. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: Efficacy, tolerability, and safety findings. Ann. Hematol. 2015, 94, 2025–2032. [Google Scholar] [CrossRef]
- Karam, M.; Ata, A.; Irish, K.; Feustel, P.J.; Mottaghy, F.M.; Stroobants, S.G.; Verhoef, G.E.; Chundru, S.; Douglas-Nikitin, V.; Wong, C.O.; et al. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. Nucl. Med. Comm. 2009, 30, 770–778. [Google Scholar] [CrossRef]
- Novelli, A.; Briones, J.; Flotats, A.; Sierra, J. PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma-Good Correlation with Clinical and Histological Features at Diagnosis. Adv. Clin. Exp. Med. 2015, 24, 325–330. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meyer, H.J.; Wienke, A.; Surov, A. Correlations Between Imaging Biomarkers and Proliferation Index Ki-67 in Lymphomas: A Systematic Review and Meta-Analysis. Clin. Lymphoma Myeloma Leuk. 2019, 19, 266–272. [Google Scholar] [CrossRef] [PubMed]
- Jaffe, E.S.; Harris, N.L.; Stein, H.; Vardinam, J.W. Tumours of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours, Pathology, and Genetics; IARC Press: Lyon, France, 2001; Volume 3. [Google Scholar]
- Albano, D.; Bosio, G.; Camoni, L.; Farina, M.; Re, A.; Tucci, A.; Giubbini, R.; Bertagna, F. Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma. Hematol. Oncol. 2019, 37, 39–46. [Google Scholar]
- Boellaard, R.; Delgado-Bolton, R.; Oyen, W.J.; Giammarile, F.; Tatsch, K.; Eschner, W.; Verzijlbergen, F.J.; Barrington, S.F.; Pike, L.C.; Weber, W.A.; et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 328–354. [Google Scholar] [CrossRef]
Variables | Patients n (%) | Average (Range) | |
---|---|---|---|
Age (years) | 65.1 (29–88) | ||
Sex | |||
male | 172 (75%) | ||
female | 57 (25%) | ||
Tumor stage at diagnosis (Ann Arbor) | |||
I | 4 (2%) | ||
II | 9 (4%) | ||
III | 32 (14%) | ||
IV | 184 (80%) | ||
Blastoid variant | 26 (11%) | ||
B symptoms | 65 (28%) | ||
LDH | |||
≤245 U/L | 121 (57%) | ||
>245 U/L | 93 (43%) | ||
β2-microglobulin | |||
≤2.8 mg/L | 108 (62%) | ||
>2.8 mg/L | 65 (38%) | ||
MIPI score | |||
low-intermediate (≤6) | 99 (43%) | ||
high-intermediate (>6) | 130 (57%) | ||
Bulky disease | 40 (17%) | ||
Splenomegaly | 101 (44%) | ||
Ki-67 score | |||
≤15% | 65 (36%) | ||
>15% | 118 (64%) |
PET/CT Findings | BM Biopsy | GI Endoscopy | ||
---|---|---|---|---|
Positive | Negative | Positive | Negative | |
Positive | 37 (16%) | 0 (0%) | 28 (12%) | 2 (1%) |
Negative | 99 (43%) | 93 (41%) | 19 (8%) | 180 (79%) |
Total | 136 (59%) | 93 (41%) | 47 (21%) | 182 (79%) |
Variables | Univariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|
p-Value | HR (95% CI) | p-Value | HR (95% CI) | |
PFS | ||||
Sex | 0.451 | 0.845 (0.548–1.306) | ||
Age | 0.153 | 1.530 (0.838–3.097) | ||
MIPI score | 0.009 | 0.713 (0.482–1.056) | 0.174 | 1.219 (0.915–1.623) |
LDH level | 0.163 | 0.742 (0.488–1.128) | ||
Β2 microglobulin | 0.458 | 0.831 (0.511–1.353) | ||
Ki-67 score | 0.066 | 0.653 (0.415–1.028) | ||
Bulky disease | 0.153 | 1.722 (0.992–2.987) | ||
Splenomegaly | 0.087 | 0.703 (0.472–01049) | ||
Stage acc Ann Arbor | 0.855 | 0.957 (0.589–1.531) | ||
Blastoid variant | 0.185 | 0.598 (0.282–1.270) | ||
Deauville score | <0.001 | 0.137 (0.073–0.259) | <0.001 | 4.059 (2.573–6.403) |
Treatment regimen | 0.655 | 0.857 (0.519–1.243) | ||
OS | ||||
Sex | 0.211 | 1.759 (0.577–6.033) | ||
Age | 0.375 | 1.270 (0.722–2.369) | ||
MIPI score | 0.025 | 0.711 (0.527–0.959) | 0.017 | 1.204 (1.032–1.403) |
LDH level | 0.709 | 0.942 (0.690–1.287) | ||
Β2 microglobulin | 0.524 | 1.128 (0.778–1.635) | ||
Ki67 score | 0.195 | 1.250 (0.891–1.754) | ||
Bulky disease | 0.390 | 0.828 (0.539–1.272) | ||
Splenomegaly | 0.287 | 0.846 (0.622–1.150) | ||
Stage acc Ann Arbor | 0.393 | 0.859 (0.606–1.217) | ||
Blastoid variant | 0.075 | 0.618 (0.363–1.051) | ||
Deauville score | 0.814 | 1.055 (0.671–1.660) | ||
Treatment regimen | 0.598 | 1.001 (0.571–1.460) |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Albano, D.; Laudicella, R.; Ferro, P.; Allocca, M.; Abenavoli, E.; Buschiazzo, A.; Castellino, A.; Chiaravalloti, A.; Cuccaro, A.; Cuppari, L.; et al. The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study. Cancers 2019, 11, 1831. https://doi.org/10.3390/cancers11121831
Albano D, Laudicella R, Ferro P, Allocca M, Abenavoli E, Buschiazzo A, Castellino A, Chiaravalloti A, Cuccaro A, Cuppari L, et al. The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study. Cancers. 2019; 11(12):1831. https://doi.org/10.3390/cancers11121831
Chicago/Turabian StyleAlbano, Domenico, Riccardo Laudicella, Paola Ferro, Michela Allocca, Elisabetta Abenavoli, Ambra Buschiazzo, Alessia Castellino, Agostino Chiaravalloti, Annarosa Cuccaro, Lea Cuppari, and et al. 2019. "The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study" Cancers 11, no. 12: 1831. https://doi.org/10.3390/cancers11121831